Completed PHASE1 INTERVENTIONAL 1-arm NCT01219348

IDO Peptid Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients. (IDOvaccine)

IDO Peptid Vaccination in Combination With Immune Stimulating Agent Aldara and the Adjuvant Montanide, for Treatment of Patients With Locally Advanced or Metastatic Non Small-cell Lung Cancer. A First-in-man Phase I Trial.

Sponsor: Inge Marie Svane

Conditions Lung Cancer NSCLC

Interventions IDO peptide vaccination

Updated 5 times since 2017 Last updated: Aug 17, 2015 Started: Jun 30, 2010 Primary completion: Aug 31, 2012 Completion: Aug 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Lung Cancer and NSCLC, this trial is completed. The trial is conducted by Inge Marie Svane and has accumulated 5 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Inge Marie Svane

Data source: Herlev Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Copenhagen, Denmark
• Herlev, Denmark